Neumora Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 0.3672 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 69.00M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and...